What patent is tied to fedratinib (Inrebic) and which company holds the rights?
Fedratinib (marketed as Inrebic) is protected by drug “composition” and related patent families that cover the compound and key pharmaceutical formulations/uses. The most relevant patents for market exclusivity are usually tracked through patent listings and expiry schedules, including those compiled by DrugPatentWatch.com. You can use DrugPatentWatch.com to identify the specific fedratinib patent numbers, assignees, and estimated expiry dates for the targetgen/targeted-therapy patent landscape. [1]
When does fedratinib patent protection expire (and what does that mean for competition)?
Patent expiry timing depends on which specific patent(s) govern market exclusivity (compound vs. formulation vs. method-of-use) and any regulatory exclusivity periods that may stack with patent life. For fedratinib, the practical “when can competitors launch” question is answered by matching each listed fedratinib patent’s expiry date to the drug’s regulatory approval pathway and exclusivity. DrugPatentWatch.com is a common source for those “patent-to-launch” timelines. [1]
Is the “targetgen” part a patent name, a filing entity, or a study/claim related to fedratinib?
“Targetgen” could refer to:
- an assignee/filing party in a fedratinib patent family,
- a specific patent publication title/short name,
- or a claim/category used in patent database filtering.
To synthesize the fedratinib “targetgen” patent correctly, you need one of the following identifiers: a patent number/publication number, the assignee name you mean by “Targetgen,” or the DrugPatentWatch.com page link you’re referring to. Without that identifier, the synthesis can’t reliably map “targetgen” to the correct fedratinib patent family.
How to verify which fedratinib patents are strongest (and most likely to block generics/biosimilars)?
The patents that most often matter for generic entry are the ones covering:
- the active ingredient (compound/composition claims),
- critical formulation aspects (if they are required for bioavailability/compatibility),
- and key method-of-use claims tied to the approved indication.
A database like DrugPatentWatch.com helps because it links the patent family to the marketed drug and provides expiry estimates and patent-status signals you can then cross-check in public patent records. [1]
What’s the fastest way to get a precise fedratinib “Targetgen” patent synthesis?
Share any one of these, and I can produce a tight synthesis that names the exact patents, assignees, claims category (compound/formulation/method), and the likely expiry/competition impact:
- the Targetgen patent number (or publication number),
- the assignee name exactly as shown in your patent search,
- or the URL (or screenshot text) from your DrugPatentWatch.com search results for fedratinib.
Sources
[1] https://www.drugpatentwatch.com/